deltatrials

Dermatitis, atopic Trials in Markham, Canada

Conditions / Dermatitis, atopic / Markham, Canada

Dermatitis, atopic is a medical condition with active clinical research programs worldwide.

20 total trials for this combination

Showing top 10 of 20 trials

Trials

NCT ID Title Status Phase
NCT05492578 Long-Term Safety and Efficacy Evaluation of Amlitelimab in Participants of Previous Amlitelimab Moderate to Severe Atopic Dermatitis Clinical Trials ENROLLING_BY_INVITATION PHASE2/PHASE3
NCT03720470 Study Evaluating Efficacy and Safety of PF-04965842 and Dupilumab in Adult Subjects With Moderate to Severe Atopic Dermatitis on Background Topical Therapy COMPLETED PHASE3
NCT03422822 Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis COMPLETED PHASE3
NCT06407934 A Study to Evaluate the Treatment Response and Safety of Two Dose Regimens of Subcutaneous Amlitelimab Compared With Treatment Withdrawal in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis ACTIVE_NOT_RECRUITING PHASE3
NCT03687359 Observational Evaluation of Atopic Dermatitis in Pediatric Patients ACTIVE_NOT_RECRUITING
NCT03428646 Study of Patients Receiving DUPIXENT® for Atopic Dermatitis (AD) ACTIVE_NOT_RECRUITING
NCT06224348 A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis on Background Topical Corticosteroids COMPLETED PHASE3
NCT03349060 Study to Evaluate Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years And Older With Moderate to Severe Atopic Dermatitis COMPLETED PHASE3
NCT03627767 Study to Investigate Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years and Over With Moderate to Severe Atopic Dermatitis With the Option of Rescue Treatment in Flaring Subjects COMPLETED PHASE3
NCT05999799 A Dose Finding Study to Investigate the Safety and Effectiveness of GSK1070806 in Adult Participants With Moderate to Severe Atopic Dermatitis TERMINATED PHASE2

Related Pages